Anne Messer

Overview

Best Publications

• Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice.

  Kevin Manley;Thomas L. Shirley;Thomas L. Shirley;Lorraine Flaherty;Lorraine Flaherty;Anne Messer;Anne Messer

  462
  Citations

• The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8.

  Susanna Ranta;Yonghui Zhang;Barbara Ross;Liina Lonka

  355
  Citations

• Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

  James A. Bibb;Zhen Yan;Per Svenningsson;Gretchen L. Snyder

  349
  Citations

• Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

  Jean-Michel Lecerf;Thomas L. Shirley;Quan Zhu;Aleksey Kazantsev

  273
  Citations

• The maintenance and identification of mouse cerebellar granule cells in monolayer culture

  Anne Messer;Anne Messer

  261
  Citations

• Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.

  David W. Colby;YiJia Chu;John P. Cassady;Martin Duennwald

  221
  Citations

• Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies

  William J. Wolfgang;Todd W. Miller;Jack M. Webster;James S. Huston

  178
  Citations

• MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice.

  Stéphanie Tomé;Kevin Manley;Kevin Manley;Jodie P. Simard;Greg W. Clark;Greg W. Clark

  177
  Citations

• A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein

  Chun Zhou;Sharareh Emadi;Michael R. Sierks;Anne Messer;Anne Messer

  146
  Citations

• Development of a Human Light Chain Variable Domain (VL) Intracellular Antibody Specific for the Amino Terminus of Huntingtin via Yeast Surface Display

  David W. Colby;Payal Garg;Tina Holden;Ginger Chao

  143
  Citations

• Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

  Tyisha Hathorn;Abigail Snyder-Keller;Abigail Snyder-Keller;Abigail Snyder-Keller;Anne Messer;Anne Messer;Anne Messer

  142
  Citations

• An scFv Intrabody against the Nonamyloid Component of α-Synuclein Reduces Intracellular Aggregation and Toxicity

  Sandra M. Lynch;Chun Zhou;Anne Messer;Anne Messer

  135
  Citations

• Dystonin is essential for maintaining neuronal cytoskeleton organization.

  Gratien Dalpé;Nicole Leclerc;Annie Vallée;Anne Messer

  135
  Citations

• Autosomal dominance in a late-onset motor neuron disease in the mouse.

  Anne Messer;Lorraine Flaherty

  121
  Citations

• Apparent Loss and Hypertrophy of Interneurons in a Mouse Model of Neuronal Ceroid Lipofuscinosis: Evidence for Partial Response to Insulin-Like Growth Factor-1 Treatment

  Jonathan D. Cooper;Anne Messer;Andrew K. Feng;Jane Chua-Couzens

  113
  Citations

• Mini-review: polybrominated diphenyl ether (PBDE) flame retardants as potential autism risk factors.

  Anne Messer

  104
  Citations

• Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments

  David C. Butler;Anne Messer;Anne Messer

  104
  Citations

• Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice

  Abigail Snyder-Keller;Julie A. McLear;Tyisha Hathorn;Anne Messer

  98
  Citations

• Intrabody Applications in Neurological Disorders: progress and Future Prospects

  Todd W. Miller;Anne Messer

  97
  Citations

• Histopathology of the late-onset motor neuron degeneration (Mnd) mutant in the mouse

  Anne Messer;Norman L. Strominger;Joseph E. Mazurkiewicz

  92
  Citations